


## DG051

<b>Cat. No.:</b>	HY-10825		
<b>CAS No.:</b>	929915-58-2		
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>25</sub> Cl <sub>2</sub> NO <sub>4</sub>		
<b>Molecular Weight:</b>	426.33		
<b>Target:</b>	Aminopeptidase		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 325 mg/mL (762.32 mM)  
 \* "≥" means soluble, but saturation unknown.

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.3456 mL	11.7280 mL	23.4560 mL
	5 mM	0.4691 mL	2.3456 mL	4.6912 mL
	10 mM	0.2346 mL	1.1728 mL	2.3456 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

DG051 is a potent leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis in the enzyme assay with an IC<sub>50</sub>=47 nM.

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 47 nM (LTA4H)<sup>[1]</sup>

#### In Vitro

DG051 is a potent inhibitor of LTA4H aminopeptidase activity against L-alanine p-nitroanilide (IC<sub>50</sub>=72 nM). DG051 inhibits human whole blood (HWB) with IC<sub>50</sub> of 37 nM. As applied within the context of LTA4H inhibitor design, the chemistry team is able to design a potent DG051(K<sub>d</sub>=26 nM) with high aqueous solubility (>30 mg/mL) and high oral bioavailability (>80% across species) that is currently undergoing clinical evaluation for the treatment of myocardial infarction and stroke<sup>[1]</sup> DG-051 is a first-in-class small molecule inhibitor of leukotriene A4 hydrolase (LTA4H), currently in Phase II clinical development for the prevention of heart attack<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

---

[1]. Sandanayaka V, et al. Discovery of 4-[(2S)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. J Med Chem. 2010 Jan 28;53(2):573-85.

[2]. Enache LA, et al. Synthesis and structural assignment of two major metabolites of the LTA4H inhibitor DG-051. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6275-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA